{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:56:13Z","timestamp":1785297373288,"version":"3.55.0"},"reference-count":38,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:p>\n                    The objective of this study is to present the complete biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced pheochromocytoma or paraganglioma. Biomarker status was assessed and post-treatment responses were analyzed for catecholamines, metanephrines, and serum chromogranin A. Complete biomarker response (normalization) or partial response, defined as at least 50% reduction from baseline if above the normal range, was evaluated at specified time points over a 12-month period. These results were correlated with two other study objectives: blood pressure control and objective tumor response as per RECIST 1.0. In this open-label, single-arm study, 68 patients received at least one therapeutic dose (~18.5 GBq (~500 mCi)) of high-specific-activity I-131 meta-iodobenzylguanidine. Of the patients, 79% and 72% had tumors associated with elevated total plasma free metanephrines and serum chromogranin A levels, respectively. Best overall biomarker responses (complete or partial response) for total plasma free metanephrines and chromogranin A were observed in 69% (37\/54) and 80% (39\/49) of patients, respectively. The best response for individual biomarkers was observed 6\u201312 months following the first administration of high-specific-activity I-131 meta-iodobenzylguanidine. Biochemical tumor marker response was significantly associated with both reduction in antihypertensive medication use (correlation coefficient 0.35;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.006) as well as objective tumor response (correlation coefficient 0.36;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.007). Treatment with high-specific-activity I-131 meta-iodobenzylguanidine resulted in long-lasting biomarker responses in patients with advanced pheochromocytoma or paraganglioma that correlated with blood pressure control and objective response rate. ClinicalTrials.gov number: NCT00874614.\n                  <\/jats:p>","DOI":"10.1530\/erc-22-0236","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:14:56Z","timestamp":1670307296000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":10,"title":["Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma"],"prefix":"10.1530","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-3355","authenticated-orcid":true,"given":"Camilo","family":"Jimenez","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett B","family":"Chin","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Noto","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Dillon","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja","family":"Solnes","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Stambler","sequence":"additional","affiliation":[{"name":"Progenics Pharmaceuticals, Inc., a Lantheus Company, North Billerica, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-4195","authenticated-orcid":true,"given":"Vincent A","family":"DiPippo","sequence":"additional","affiliation":[{"name":"Progenics Pharmaceuticals, Inc., a Lantheus Company, North Billerica, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Pryma","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2110","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","unstructured":"Amar LServais AGimenez-Roqueplo APZinzindohoue FChatellier GPlouin PF2005Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. Journal of Clinical Endocrinology and Metabolism902110\u20132116. (https:\/\/doi.org\/10.1210\/jc.2004-1398)"},{"key":"bib2","series-title":"Cancer","first-page":"2804","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez MFeng LHabra MARich TDickson PVPerrier NPhan AWaguespack SPatel SJimenez C2012Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer1182804\u20132812. (https:\/\/doi.org\/10.1002\/cncr.26577)"},{"key":"bib3","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"717","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez MFeng LJohnson MMEjaz SHabra MARich TBusaidy NCote GJPerrier NPhan A2011Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. Journal of Clinical Endocrinology and Metabolism96717\u2013725. (https:\/\/doi.org\/10.1210\/jc.2010-1946)"},{"key":"bib39","year":"2021","unstructured":"AZEDRA\u00ae2021 Full prescribing information | AZEDRA\u00ae (iobenguane | 131). Billercia, MA, USA: Progenics Pharmaceuticals Inc., a Lantheus Company. (available at: https:\/\/www.azedra.com\/content\/pdf\/full-prescribing-information.pdf)"},{"key":"bib5","series-title":"Cancer Biotherapy and Radiopharmaceuticals","first-page":"299","article-title":"Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution","volume":"25","author":"Barrett","year":"2010","unstructured":"Barrett JAJoyal JLHillier SMMaresca KPFemia FJKronauge JFBoyd MMairs RJBabich JW2010Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biotherapy and Radiopharmaceuticals25299\u2013308. (https:\/\/doi.org\/10.1089\/cbr.2009.0695)"},{"key":"bib6","series-title":"Cancer Biotherapy and Radiopharmaceuticals","first-page":"469","article-title":"Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"Coleman","year":"2009","unstructured":"Coleman REStubbs JBBarrett JAde la Guardia MLafrance NBabich JW2009Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid. Cancer Biotherapy and Radiopharmaceuticals24469\u2013475. (https:\/\/doi.org\/10.1089\/cbr.2008.0584)"},{"key":"bib7","series-title":"Endocrine Connections","first-page":"R87","article-title":"Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations","volume":"6","author":"Corcuff","year":"2017","unstructured":"Corcuff JBChardon LEl Hajji Ridah IBrossaud J2017Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocrine Connections6R87\u2013R98. (https:\/\/doi.org\/10.1530\/EC-17-0071)"},{"key":"bib8","series-title":"Endocrine Connections","first-page":"186","article-title":"Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center","volume":"7","author":"Falhammar","year":"2018","unstructured":"Falhammar HKjellman MCalissendorff J2018Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocrine Connections7186\u2013192. (https:\/\/doi.org\/10.1530\/EC-17-0321)"},{"key":"bib9","series-title":"Journal of Urology","first-page":"1583","article-title":"Predictive factors for malignant pheochromocytoma: analysis of 136 patients","volume":"185","author":"Feng","year":"2011","unstructured":"Feng FZhu YWang XWu YZhou WJin XZhang RSun FKasoma ZShen Z2011Predictive factors for malignant pheochromocytoma: analysis of 136 patients. Journal of Urology1851583\u20131590. (https:\/\/doi.org\/10.1016\/j.juro.2010.12.050)"},{"key":"bib10","series-title":"Pancreas","first-page":"469","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","unstructured":"Fishbein LDel Rivero JElse THowe JRAsa SLCohen DLDahia PLMFraker DLGoodman KAHope TA2021The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma. Pancreas50469\u2013493. (https:\/\/doi.org\/10.1097\/MPA.0000000000001792)"},{"key":"bib11","series-title":"Journal of Clinical Oncology","first-page":"4162","article-title":"Phase II study of high-dose (131I)metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","unstructured":"Gonias SGoldsby RMatthay KKHawkins RPrice DHuberty JDamon LLinker CSznewajs AShiboski S2009Phase II study of high-dose (131I)metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Journal of Clinical Oncology274162\u20134168. (https:\/\/doi.org\/10.1200\/JCO.2008.21.3496)"},{"key":"bib12","series-title":"Cancer Control","first-page":"104","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan","year":"2011","unstructured":"Grogan RHMitmaker EJDuh QY2011Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control18104\u2013112. (https:\/\/doi.org\/10.1177\/107327481101800205)"},{"key":"bib13","series-title":"Archives of Medical Science","first-page":"1","article-title":"Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls","volume":"12","author":"Gut","year":"2016","unstructured":"Gut PCzarnywojtek AFischbach JB\u0105czyk MZiemnicka KWrotkowska EGryczy\u0144ska MRucha\u0142a M2016Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Archives of Medical Science121\u20139. (https:\/\/doi.org\/10.5114\/aoms.2016.57577)"},{"key":"bib14","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3296","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","unstructured":"Hamidi OYoung WFJrIniguez-Ariza NMKittah NEGruber LBancos CTamhane SBancos I2017Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. Journal of Clinical Endocrinology and Metabolism1023296\u20133305. (https:\/\/doi.org\/10.1210\/jc.2017-00992)"},{"key":"bib15","series-title":"Frontiers in Endocrinology (Lausanne)","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","unstructured":"Jimenez C2018Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer. Frontiers in Endocrinology (Lausanne)9 277. (https:\/\/doi.org\/10.3389\/fendo.2018.00277)"},{"key":"bib16","series-title":"Cancers","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","unstructured":"Jimenez CErwin WChasen B2019Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers11 1018. (https:\/\/doi.org\/10.3390\/cancers11071018)"},{"key":"bib17","series-title":"Journal of the National Cancer Institute","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","unstructured":"Therasse PArbuck SGEisenhauer EAWanders JKaplan RSRubinstein LVerweij JVan Glabbeke Mvan Oosterom ATChristian MC2000New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute92205\u2013216. (https:\/\/doi.org\/10.1093\/jnci\/92.3.205)"},{"key":"bib18","series-title":"Endocrine-Related Cancer","first-page":"405","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","unstructured":"Kimura NTakayanagi RTakizawa NItagaki EKatabami TKakoi NRakugi HIkeda YTanabe ANigawara T2014Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocrine-Related Cancer21405\u2013414. (https:\/\/doi.org\/10.1530\/ERC-13-0494)"},{"key":"bib19","series-title":"Pancreas","first-page":"557","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","unstructured":"Kunz PLReidy-Lagunes DAnthony LBBertino EMBrendtro KChan JAChen HJensen RTKim MKKlimstra DS2013Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas42557\u2013577. (https:\/\/doi.org\/10.1097\/MPA.0b013e31828e34a4)"},{"key":"bib20","series-title":"Endocrine Pathology","first-page":"213","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","unstructured":"Lam AK2017Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocrine Pathology28213\u2013227. (https:\/\/doi.org\/10.1007\/s12022-017-9484-5)"},{"key":"bib21","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1915","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","unstructured":"Lenders JWMDuh QYEisenhofer GGimenez-Roqueplo APGrebe SKGMurad MHNaruse MPacak KYoung WFJr & Endocrine Society2014Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism991915\u20131942. (https:\/\/doi.org\/10.1210\/jc.2014-1498)"},{"key":"bib22","series-title":"Journal of Endocrinological Investigation","first-page":"648","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","unstructured":"Loh KCFitzgerald PAMatthay KKYeo PPBPrice DC1997The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Journal of Endocrinological Investigation20648\u2013658. (https:\/\/doi.org\/10.1007\/BF03348026)"},{"key":"bib23","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"E1731","article-title":"Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects","volume":"97","author":"Mosli","year":"2012","unstructured":"Mosli HHDennis AKocha WAsher LJVan Uum SHM2012Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. Journal of Clinical Endocrinology and Metabolism97E1731\u2013E1735. (https:\/\/doi.org\/10.1210\/jc.2012-1548)"},{"key":"bib24","series-title":"Clinical Endocrinology","first-page":"642","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","unstructured":"Niemeijer NDAlblas Gvan Hulsteijn LTDekkers OMCorssmit EPM2014Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clinical Endocrinology81642\u2013651. (https:\/\/doi.org\/10.1111\/cen.12542)"},{"key":"bib25","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"213","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","unstructured":"Noto RBPryma DAJensen JLin TStambler NStrack TWong VGoldsmith SJ2018Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma. Journal of Clinical Endocrinology and Metabolism103213\u2013220. (https:\/\/doi.org\/10.1210\/jc.2017-02030)"},{"key":"bib26","series-title":"Endocrine Practice","first-page":"318","article-title":"Chromogranin A in a cohort of pheochromocytomas and paragangliomas: usefulness at diagnosis and as an early biomarker of recurrence","volume":"27","author":"Parisien-La Salle","year":"2021","unstructured":"Parisien-La Salle SProven\u00e7al MBourdeau I2021Chromogranin A in a cohort of pheochromocytomas and paragangliomas: usefulness at diagnosis and as an early biomarker of recurrence. Endocrine Practice27318\u2013325. (https:\/\/doi.org\/10.1016\/j.eprac.2020.09.011)"},{"key":"bib27","series-title":"European Journal of Endocrinology","first-page":"G1","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","unstructured":"Plouin PFAmar LDekkers OMFassnacht MGimenez-Roqueplo APLenders JWMLussey-Lepoutre CSteichen O & Guideline Working Group2016European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. European Journal of Endocrinology174G1\u2013G10. (https:\/\/doi.org\/10.1530\/EJE-16-0033)"},{"key":"bib28","series-title":"Hormone and Metabolic Research","first-page":"390","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","unstructured":"Plouin PFFitzgerald PRich TAyala-Ramirez MPerrier NDBaudin EJimenez C2012Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Hormone and Metabolic Research44390\u2013399. (https:\/\/doi.org\/10.1055\/s-0031-1299707)"},{"key":"bib29","series-title":"Journal of Nuclear Medicine","first-page":"623","article-title":"Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","unstructured":"Pryma DAChin BBNoto RBDillon JSPerkins SSolnes LKostakoglu LSerafini ANPampaloni MHJensen J2019Efficacy and safety of high-specific-activity I-131 MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. Journal of Nuclear Medicine60623\u2013630. (https:\/\/doi.org\/10.2967\/jnumed.118.217463)"},{"key":"bib30","series-title":"Annals of Surgery","first-page":"172","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez AZhou SAyala-Ramirez MShen CWaguespack SGHabra MAKaram JAPerrier NWood CGJimenez C2018Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Annals of Surgery268172\u2013178. (https:\/\/doi.org\/10.1097\/SLA.0000000000002195)"},{"key":"bib31","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"553","article-title":"A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka","year":"2003","unstructured":"Sawka AMJaeschke RSingh RJYoung WFJr2003A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Journal of Clinical Endocrinology and Metabolism88553\u2013558. (https:\/\/doi.org\/10.1210\/jc.2002-021251)"},{"key":"bib32","series-title":"European Journal of Endocrinology","first-page":"377","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","unstructured":"Thosani SAyala-Ramirez MRoman-Gonzalez AZhou SThosani NBisanz AJimenez C2015Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. European Journal of Endocrinology173377\u2013387. (https:\/\/doi.org\/10.1530\/EJE-15-0456)"},{"key":"bib33","series-title":"Applied Radiation and Isotopes","first-page":"621","article-title":"No-carrier-added synthesis of meta-(131I)iodobenzylguanidine","volume":"44","author":"Vaidyanathan","year":"1993","unstructured":"Vaidyanathan GZalutsky MR1993No-carrier-added synthesis of meta-(131I)iodobenzylguanidine. Applied Radiation and Isotopes44621\u2013628. (https:\/\/doi.org\/10.1016\/0969-8043(9390179-E)"},{"key":"bib34","series-title":"Seminars in Nuclear Medicine","first-page":"324","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","unstructured":"Vallabhajosula SNikolopoulou A2011Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Seminars in Nuclear Medicine41324\u2013333. (https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.05.003)"},{"key":"bib35","series-title":"European Journal of Endocrinology","first-page":"R109","article-title":"Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma","volume":"170","author":"van Berkel","year":"2014","unstructured":"van Berkel ALenders JWTimmers HJ2014Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. European Journal of Endocrinology170R109\u2013R119. (https:\/\/doi.org\/10.1530\/EJE-13-0882)"},{"key":"bib36","series-title":"Clinical Endocrinology","first-page":"487","article-title":"2014 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LTNiemeijer NDDekkers OMCorssmit EPM20142014 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clinical Endocrinology80487\u2013501. (https:\/\/doi.org\/10.1111\/cen.12341)"},{"key":"bib37","series-title":"Scientific Reports","article-title":"A phase I clinical trial for ((131)I)meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma","volume":"9","author":"Wakabayashi","year":"2019","unstructured":"Wakabayashi HInaki AYoshimura KMurayama TImai YHiguchi TJinguji MShiga TKinuya S2019A phase I clinical trial for ((131)I)meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Scientific Reports9 7625. (https:\/\/doi.org\/10.1038\/s41598-019-43880-6)"},{"key":"bib38","series-title":"Hormone and Metabolic Research","first-page":"379","article-title":"High incidence of cardiovascular complications in pheochromocytoma","volume":"44","author":"Zelinka","year":"2012","unstructured":"Zelinka TPetr\u00e1k OTurkov\u00e1 HHolaj R\u0160trauch BKr\u0161ek MVr\u00e1nkov\u00e1 ABMusil ZDu\u0161kov\u00e1 JKubinyi J2012High incidence of cardiovascular complications in pheochromocytoma. Hormone and Metabolic Research44379\u2013384. (https:\/\/doi.org\/10.1055\/s-0032-1306294)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/30\/2\/ERC-22-0236.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/30\/2\/ERC-22-0236.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/30\/2\/ERC-22-0236.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:22Z","timestamp":1784555782000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":38,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/erc-22-0236","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}